Julia W. Korzilius

Dr. Julia W. Korzilius


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Clinical Nutrition
Verified
Journal Article
Closed access
DDDorian N. Dijxhoorn
Dorian N. Dijxhoorn
MBManon G.A. van Den Berg
Manon G.A. van Den Berg
WKWietske Kievit
Wietske Kievit
JKJulia W. Korzilius
Julia W. Korzilius
JDJoost Drenth
Joost Drenth
GWGeert Wanten
Geert Wanten

31 October 2023 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
JKJulia W. Korzilius
Julia W. Korzilius
SOSosha E. Oppenheimer
Sosha E. Oppenheimer
NRNicole M. de Roos
Nicole M. de Roos
GWGeert J. A. Wanten
Geert J. A. Wanten
HZHeidi Zweers
Heidi Zweers
Background: Bioelectrical impedance analysis (BIA) is commonly used to evaluate body composition as part of nutritional assessment. Current guidelines recommend performing BIA measurements in a fasting state of at least 2 h in a clinical setting and 8 h in a research setting. However, since asking patients with malnutrition or sarcopenia to fast is not desirable and literature to support the strategy in the guidelines is lacking, this study aimed to assess the impact of breakfast on BIA measurements. Methods: We performed an explorative, prospective study in healthy volunteers aged between 18 and 70 years, with a normal fluid balance and a body mass index between 18.5 and 30 kg/m2. BIA measurements were performed according to the standard operating procedure in the fasting state, and 1, 2, 3, and 4 h after ingesting a standardized breakfast meal of about 400 kcal with a 150 mL drink, using the hand-to-food single-frequency BIA (Bodystat500 ®). The Kyle formula was used to calculate the primary outcome, i.e. fat-free mass (FFM, kg). A linear mixed model was used to compare baseline values with other time points. A difference of 1 kg in FFM was considered clinically relevant. Results: Thirty-nine (85% female) volunteers were included, with a median age of 28 years (IQR 24–38). In 90% of the participants, having breakfast had no clinically relevant impact on the estimated FFM. For the group, the most pronounced mean difference, a statistically but not clinically significant higher value of 0.2 kg (0.4%), was observed after 3 h of fasting compared to baseline. No statistically significant differences were found at the other time points. Conclusion: Eating affects single-frequency BIA measurements, but differences in FFM remain below clinical relevance for most participants when using a standardized breakfast. Thus, the current study suggests performing a BIA measurement in a fasting state is not required.

30 June 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JKJulia W. Korzilius
Julia W. Korzilius
Michelle GompelmanMichelle Gompelman
Michelle Gompelman
GWGuus T J Wezendonk
Guus T J Wezendonk
NJNynke G L Jager
Nynke G L Jager
CRChantal P Rovers
Chantal P Rovers
GWGeert J A Wanten
Geert J A Wanten
Background: The use of oral antimicrobial agents in patients with short bowel syndrome (SBS) is challenging due to the changes in gastrointestinal anatomy that may result in diminished absorption and altered drug bioavailability. Prospective studies evaluating bioavailability of antimicrobial agents after oral administration in SBS patients are lacking. Objectives: To determine the bioavailability of orally administered antimicrobial agents commonly used for treatment in SBS patients to guide clinical decision making when faced with infections. Methods: We performed an explorative, clinical study investigating the pharmacokinetics (PK) of clindamycin, ciprofloxacin, flucloxacillin and fluconazole in SBS patients with intestinal failure. Participants received a combination of two antimicrobial agents simultaneously. To determine the oral bioavailability, participants received a single oral and IV dose of both agents on two occasions, after which they underwent intensive PK sampling on six predefined time points up to 12 hours after administration. Primary outcome was the oral bioavailability of these antimicrobial agents. Secondary outcomes were intravenous PK characteristics following non-compartmental analysis. Results: Eighteen SBS patients were included: the mean (SD) age was 59 (17) years and 61% of participants were female. The median observed (IQR) bioavailability of ciprofloxacin, clindamycin, flucloxacillin and fluconazole were 36% (24–50), 93% (56–106), 50% (32–76) and 98% (61–107), respectively. Conclusion: The bioavailability of selected antimicrobial agents in certain patients with SBS appeared to be better than expected, providing a feasible treatment option. Due to the large observed differences between patients, therapeutic drug monitoring should be part of the treatment to safeguard adequate exposure in all patients. Trial registration: Registered in the Dutch Trial Register (NL7796) and EudraCT number 2019-002587-28

31 July 2022 in Clinical Nutrition
Verified
Journal Article
Open access
JKJulia W. Korzilius
Julia W. Korzilius
VGV.E.L.M. Gillis
V.E.L.M. Gillis
YWY. Wouters
Y. Wouters
GWG.J.A. Wanten
G.J.A. Wanten
A catheter-related bloodstream infection (CRBSI) is a serious complication of home parenteral nutrition (HPN) treatment. Despite taurolidine's frequent use as catheter lock solution (CLS) to prevent CRBSIs and its presumed favourable safety profile, data on taurolidine-related adverse events (AEs) and the clinical implications thereof remain merely anecdotal. Aim of this study was to explore taurolidine-related AEs in our large cohort of HPN patients and to develop an algorithm on how to deal with these AEs in clinical practice. This retrospective cohort study comprised all adult HPN patients who used taurolidine as a CLS between 2006 and 2021 at our national HPN referral centre. Primary outcome was to identify taurolidine-related AEs. Secondary outcomes were median time to a taurolidine-related AEs and development of a clinical algorithm. A taurolidine-related AE was defined as an event that occurred directly after instillation of taurolidine in the CVAD or at start of fluid/PN infusion. In total, 470 patients used taurolidine during 700.232 catheter days. In 89 (19%) patients, 103 mild- to severe AEs related to taurolidine were observed. Six patients developed an allergic reaction. Reported AEs compromised vascular access device-related problems (group A) or taurolidine-related problems (group B) in 53 (51%) and 50 (49%), patients, respectively. In groups A and B, 51 (85%) and 21 (18%) patients presented with taurolidine infusion-related pain. Upon rechallenge, 45 (85%) and 16 (32%) patients, respectively, successfully resumed taurolidine locking without residual symptoms. In this study, use of taurolidine as CLS was generally safe. Most reported AEs were vascular access device-related, and the majority of symptoms concerned pain. Upon rechallenge, a substantial number of patients, especially those in whom pain was the main symptom, could resume CLS locking after addressing the underlying catheter-related problem. Based on these results, we present a clinical algorithm for patients with possible taurolidine-related symptoms.

8 June 2024 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
JKJulia W. Korzilius
Julia W. Korzilius
MAMonique Johanna Margaretha Dorothea van Asseldonk
Monique Johanna Margaretha Dorothea van Asseldonk
GWGeert Jacobus Antonius Wanten
Geert Jacobus Antonius Wanten
HZheidi Zweers
heidi Zweers
Background: Chronic intestinal failure (CIF) refers to the long‐lasting reduction of gut function below the minimum necessary to absorb macronutrients, water, and/or electrolytes. Patients with CIF likely develop various forms of malnutrition and dehydration, yet studies that focus primarily on body composition are lacking. Therefore, this study aimed to evaluate the body composition of adult patients with CIF.Methods: This retrospective descriptive cohort study was performed at the Radboud University Medical Center, a tertiary referral center for CIF treatment in the form of home parenteral nutrition. We collected available bioelectrical impedance analysis (BIA) data from routine care between 2019 and 2023. The primary outcome was body composition, which was evaluated by assessing body mass index (BMI), fat‐free mass index (FFMI), and fat percentage (fat%).Results: Overall, 147 adult patients with CIF were included with a median (interquartile range) age of 58 (25–68) years; 69% were female. The mean (SD) BMI was 22.1 (4.3) kg/m2, FFMI was 14.2 (1.9) kg/m2 in females and 17.0 (2.0) kg/m2 in males, and fat% was 33.7% (6.8%) in females and 24.6% (6.4%) in males. 63% had an FFMI below references, and 48% had a high fat%.Conclusion: This study found that most adult patients with CIF have an unfavorable body composition characterized by a high fat% and low FFMI despite having a normal mean BMI. These results highlight the necessity for in‐depth nutrition assessment, including BIA measurement. Moreover, future studies should focus on exercise interventions to increase FFMI and improve body composition and function.

5 January 2025 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
PDF file
JKJulia W. Korzilius
Julia W. Korzilius
MDManon Dumont
Manon Dumont
HJHarriët Jager‐Wittenaar
Harriët Jager‐Wittenaar
GWGeert J. A. Wanten
Geert J. A. Wanten
HZheidi Zweers
heidi Zweers
Background: In patients with chronic intestinal failure, the content and type of parenteral nutrition are individually determined based on various factors, including body composition. In clinical practice, bioelectrical impedance analysis is used to assess body composition using standardized protocols. However, these protocols lack specific recommendations for patients receiving parenteral nutrition. Therefore, this study described the effect of parenteral nutrition infusion on fat‐free mass as evaluated by single‐frequency bioelectrical impedance analysis.Methods: We performed a descriptive cohort study using bioelectrical impedance analysis to assess adult patients with chronic intestinal failure receiving parenteral nutrition. Measurements were performed at baseline (before parenteral nutrition infusion) and 0, 1, 2, and 4 h after (usually) 18‐h parenteral nutrition infusion using hand‐to‐foot single‐frequency bioelectrical impedance analysis (Bodystat 500). The primary outcome of fat‐free mass was calculated using the Kyle equation. A linear mixed model was used to compare baseline values with other time points. A difference of >1 kg in fat‐free mass compared with baseline was considered clinically relevant.Results: Twenty patients (70% female) with a mean age of 58 (SD, 14) years and a median body mass index of 22.3 (IQR, 21.2–24.8) kg/m2 were included in the analysis. No significant change in fat‐free mass after parenteral nutrition infusion was observed, and 90% (69/77 measurements) of all fat‐free mass outcomes after parenteral nutrition infusion remained within the ≤1‐kg clinically relevant range.Conclusion: This study found that parenteral nutrition infusion does not affect fat‐free mass estimation as assessed by hand‐to‐foot single‐frequency bioelectrical impedance analysis.